Key Takeaways
Neko Health announced a $700 million Series C on July 15, led by Lightspeed Venture Partners and co-led by O.G. Venture Partners, to fund its first US clinics starting with Manhattan later this year.
More than 100,000 people in the UK and Sweden have taken the 60-minute, radiation-free scan, over 350,000 are on the waitlist, and 75% of members prepay for the next year's scan before leaving.
Media reports put the new valuation near $7 billion, roughly four times the company's Series B mark from January 2025.
Neko Health, the preventive health company founded by Spotify's Daniel Ek and Hjalmar Nilsonne, announced a $700 million Series C on July 15 to fund its US launch, with its first American clinic opening in Manhattan later this year. Lightspeed Venture Partners led the round, O.G. Venture Partners co-led, and reports peg the valuation near $7 billion, about four times where the company sat after its $260 million Series B in January 2025.
The product is a 60-minute, non-invasive, radiation-free scan that captures millions of data points across skin, heart and blood, with results explained by a doctor the same visit. It costs £299 in the UK. More than 100,000 people in the UK and Sweden have taken one, more than 350,000 are on the waitlist, and 75% of members book and prepay the next year's scan before they leave the building.
The company also published outcome data worth sitting with. Among returning members whose first scan flagged a severe or life-threatening condition, three in four were in good health or had the condition under control by their second visit. Nilsonne said the round takes the mission to the US for the first time, describing the goal as to "catch problems early and help prevent disease before it even starts."
The backer list reads like a culture shift, with Mark Zuckerberg and Priscilla Chan, Tim Ferriss, Maria Sharapova and will.i.am all participating. Healthcare systems on both sides of the Atlantic are pushing toward prevention, and consumers are paying out of pocket to get there first. We have covered that shift before, from Life Biosciences dosing the first patient in a cellular rejuvenation trial to the protocol for sequencing your own genome at home. A $700 million bet on catching disease early is the clearest signal yet of where the money thinks this goes.
People Also Ask
What is the Neko Health scan and how much does it cost?
A 60-minute, non-invasive, radiation-free health assessment that combines proprietary sensors with blood analysis to check skin, cardiovascular risk, pre-diabetes markers and blood abnormalities. Results arrive within minutes and are reviewed with a doctor on site. It costs £299 in the UK and 2,750 SEK in Sweden.
Who invested in Neko Health's $700 million Series C?
Lightspeed Venture Partners led with O.G. Venture Partners co-leading, joined by Atomico, General Catalyst and Lakestar, plus individuals including Mark Zuckerberg and Priscilla Chan, Tim Ferriss, Maria Sharapova, Thierry Henry and will.i.am.
When is Neko Health coming to the US?
The first US clinic opens in Manhattan later in 2026, with more American cities planned. Waitlist signups are being promised first access to the New York location.
Does the Neko scan actually catch disease early?
The company reports that three in four returning members with previously identified severe or life-threatening conditions were in good health or had the condition under control by their second scan, and that five of seven key biomarkers showed statistically significant improvement between visits. That is company data, not an independent clinical trial.